DDInter1843 DDInter150
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Trandolapril {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trandolapril {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) HSD17B11
HSD17B11 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Trandolapril {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trandolapril (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Trandolapril may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) upregulates HSD17B11 (Gene) and HSD17B11 (Gene) is upregulated by Azathioprine (Compound)
Trandolapril may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)